History

From business startup to our company foundation

Apr. 1988 With the objective of supporting research and development of DDS (drug delivery system)-related technologies, LTT Research Institute was established by Yutaka Mizushima.
Jun. 1988 A DDS product (liposteroid: Brand name/Limethason®) was marketed by Green Cross Corporation (current Mitsubishi Tanabe Pharma Corporation)
July. 1988 A DDS product (liposteroid:product name/Haloart®, Haloart®S) was marketed by Taiho Pharmaceutical Co., Ltd.
Oct. 1988 A DDS product(lipo-PGE1: Product name/Palux®Injection) was marketed by Taisho Pharmaceutical Co., Ltd.
Nov. 1988 A DDS product(lipo-PGE1:Product name/Liple®Injection) was marketed by Green Cross Corporation (current Mitsubishi Tanabe Pharma Corporation)
Collaborative research was started with St. Marianna University School of Medicine
Yutaka Mizushima received the Drug Formulation Technology Award of the Academy of Pharmaceutical Science and Technology, Japan for the invention and development of lipo products.
Oct. 1990 Institute of Medical Science, St. Marianna University School of Medicine, was established by Yutaka Mizushima and his colleagues(the first head of the institute: Yutaka Mizushima)
Jun. 1992 A DDS product (non-steroidal lipo product:Product name/Ropion®) was marketed by Kaken Pharmaceutical Co., Ltd.
Mar. 1995 Beijing Tide Pharmaceutical Co., Ltd., was established jointly with China-Japan Friendship Hospital (Beijing, China).
Manufacturing and development of a DDS product (lipo-PGE1: Product name/Kaishi) was started in China with technical support from Taisho Pharmaceutical Co., Ltd.
Sep. 1997 A DDS product (lipo-PGE1:Product name/Kaishi) was marketed by Beijing Tide Pharmaceutical Co., Ltd.
Sep. 1998 A DDS product (lipo-steroid:Product name/Farnezone) was marketed by Taiho Pharmaceutical Co., Ltd.
A DDS product (lipo-steroid: Product name/Farnerate) was marketed by Dainippon Pharmaceutical Co., Ltd. (current Dainippon Sumitomo Pharmaceutical Co., Ltd.)
Sep. 2001 Yutaka Mizushima received the Chinese Government Friendship Award for development of lipo products in China.

From company foundation to the present

Jan. 2003 LTT Bio-Pharma was founded by the corporate separation from the LTT Research Institute to transfer the pharmaceutical business.
Oct. 2004 A DDS product (non-steroidal lipo product: Product name/Kaifen) was marketed by Beijing Tide Pharmaceutical Co., Ltd.
Nov. 2004 LTT Bio-Pharma was listed on TSE Mothers.
Jun. 2005 Obagi Perfect Lift AA, a product developed based on our DDS technology, was marketed by Rohto Pharmaceutical Co., Ltd.
Oct. 2005 Sole Corporation (a wholly owned subsidiary) was established to enter the dispensing pharmacy market.
Mar. 2006 Research Institute for Drug Discovery, School of Pharmacy, Kumamoto University, was established by Tohru Mizushima (Professor of Kumamoto University) and his colleagues (the first head of the institute: Tohru Mizushima).
A new donate course (Advanced DDS Studies) was established by LTT Bio-Pharma.
Jun. 2006 A collaborative business agreement for manufacturing and marketing of MH-processed tableting pestle was concluded with Machine Parts Co., Ltd.
Nov. 2006 An Early Phase Ⅱ clinical study of PC-SOD (injectable), a DDS product, was completed in Japan.
This study showed that PC-SOD was effective for ulcerative colitis.
Aug. 2007 LTT Bio-Pharma had an exclusive license agreement for PC-SOD in all regions of China with Beijing Tide Pharma.
Sep. 2007 Asklepios Co., Ltd., was wholly owned by exchanging shares.
Mar. 2008 Asklepios Co., Ltd., a subsidiary, filed for bankruptcy, and the company was excluded from the consolidated companies.
May. 2008 Yutaka Mizushima, the founder, died of acute heart failure.
Jun. 2008 An early phase Ⅱ clinical study of PC-SOD (injectable), a DDS product, was completed in Japan. This study showed that PC-SOD was effective for idiopathic interstitial pneumonia.
Jun. 2008 Tohru Mizushima was appointed the second chair of the Board of Directors.
Oct. 2008 Machine Parts Hanbai Co., Ltd., (wholly owned subsidiary) was established for marketing of EIP products
Feb. 2009 The head office was moved to Shiodome Building in Kaigan, Minato-ku, Tokyo.
Feb. 2009 LTT Bio-Pharma Transferred all stocks of Sole Corporation.
The company was excluded from consolidated companies.
Apr. 2009 Capital and business alliance agreement was concluded with Beijing Tide Pharmaceutical Co., Ltd.
Aug. 2009 Practical Application of PC-SOD NE was selected for a research program granted by the New Energy and Industrial Technology Development Organization (NEDO).
Sep. 2009 LTT Bio-Pharma had an exclusive license agreement forAS-013 in all regions of China with Beijing Tide Pharma.
Dec. 2009 A toxicology study was started for actual application of PC-SOD NE.
Jan. 2010 LTT Bio-Pharma concluded a collaborative research agreement (Stealth Type Nano-Particles) with Asahi Kasei Pharma to start basic research.
A toxicology study of the actual application of PC-SOD NE was started.
May. 2010 LLT Bio-Pharma acquired a patent for the composition (substances) of PC-SOD, a DDS product, in the US.
Jun. 2010 PC-SOD, a DDS product, was designated as an orphan drug by the Ministry of Health, Labour and Welfare.
Jul. 2010 Actual Application of Stealth Type Nano-Particle PGE1Formulation was selected for a research program granted by the New Energy and Industrial Technology Development Organization (NEDO).
Sep. 2010 A phase I clinical study of PC-SOD NE was started.
Nov. 2010 LTT Bio-Pharma had a collaborative research and development agreement with Beijing Tide Pharmaceutical Co., Ltd., on Stealth Type Nano-Particles.
Dec. 2010 A repeated-dose phase I study of PC-SOD NE on healthy volunteers was started.
Mar. 2011 LLT Bio-Pharma withdrew from EIP business operations.
Mar. 2011 Tohru Mizushima received the Pharmaceutical Society of Japan Science Promotion Award for drug repositioning (DR) research.
Apr. 2011 LTT Bio-Pharma’s stocks were assigned as Securities under Supervision (as of April 1. 2011)
Jul. 2011 LTT Bio-Pharma’s stocks were securities to be put on the delisting post (as of July 8. 2011).
Jul. 2011 LTT Bio-Pharma had an exclusive license agreement for PC-SOD NE in all regions of Korea with Chon Kun Dang Pharma Corp.
Aug. 2011 LTT Bio-Pharma’s stocks were delisted (as of Aug 9. 2011).
Feb. 2012 Reduced the capital toa hundred million yen (as of Feb. 10. 2012).
Machine Parts Co., Ltd., was excluded from the scope of consolidated subsidiaries to be liquidated.
A phase I clinical study of PC-SOD NE was completed.
Jul. 2012 A phase Ⅱ global clinical study of PC-SOD NE was started.
Jul. 2013 Tohru Mizushima received the Nagai Award of the Japan Society of Drug Delivery System for research on PC-SOD.
Sep. 2014 A phase Ⅱ clinical study of PC-SOD NE was completed.
May. 2015 Tohru Mizushima received the Applied Research Award of Kihara Memorial Foundation for research on drug repositioning (DR).
Jun. 2015 Beijing Tide Pharmaceutical Co., Ltd.., received approval for phase I and phase Ⅱ clinical studies of PC-SOD in China.
Oct. 2015 LTT Bio-Pharma concluded a license contract of pipeline (LT-4004) with Ajinomoto Pharma Co., Ltd.
Apr. 2016 LTT Bio-Pharma established a donated research division (advanced drug discovery course) at St. Marianna University School of Medicine.
May. 2016 An early phase Ⅱ clinical study of drug for the treatment of dry eye (LT-4002) was started.
Apr. 2017 An early phase Ⅱ clinical study of drug for the treatment of dry eye (LT-4002) was completed.
Mar. 2018 LTT Bio-Pharma concluded a basic collaborative development agreement for additional indication of the existing drugs (drug repositioning (DR)) with Nobelpharma Co., Ltd.
Feb. 2019 LLT-Bio Pharma established our institute (Shonan Institute) at the Shonan Health Innovation Park (Shonan i-park).
Apr. 2019 A phase Ⅱ clinical study of the product developed jointly with Nobelpharma Co., Ltd., (LT-5001) was started.
Apr. 2019 A later phase Ⅱ clinical study of drug for the treatment of dry eye (LT-4002) was started.